Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.47%) $27.23
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

リアルタイムの更新： Formycon AG [FYB.DE]

取引所: XETRA セクター: Biotechnology 産業: Biotechnology
最終更新日時27 4月 2024 @ 00:36
25% discount on Stockinvest.us - Use code: Podcast

0.63% € 39.95

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 00:36):

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials...

Stats
本日の出来高 4 802.00
平均出来高 8 148.00
時価総額 705.39M
EPS €0 ( 2024-04-25 )
次の収益日 ( €0 ) 2024-05-28
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E -10.57
ATR14 €0.0780 (0.20%)

ボリューム 相関

長: 0.01 (neutral)
短: 0.49 (neutral)
Signal:(58.761) Neutral

Formycon AG 相関

10 最も正の相関
10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Formycon AG 相関 - 通貨/商品

The country flag -0.47
( neutral )
The country flag -0.46
( neutral )
The country flag 0.00
( neutral )
The country flag -0.40
( neutral )
The country flag 0.42
( neutral )
The country flag 0.36
( neutral )

Formycon AG 財務諸表

Annual 2022
収益: €42.50M
総利益: €12.07M (28.41 %)
EPS: €2.62
FY 2022
収益: €42.50M
総利益: €12.07M (28.41 %)
EPS: €2.62
FY 2021
収益: €36.97M
総利益: €1.01M (2.72 %)
EPS: €-1.225
FY 2020
収益: €34.23M
総利益: €8.76M (25.60 %)
EPS: €-0.539

Financial Reports:

No articles found.

Formycon AG

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。